{"name":"Radiomedix, Inc.","slug":"radiomedix-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"64Cu-DOTATATE","genericName":"64Cu-DOTATATE","slug":"64cu-dotatate","indication":"Imaging of somatostatin receptor-positive neuroendocrine tumors","status":"phase_3"}]}],"pipeline":[{"name":"64Cu-DOTATATE","genericName":"64Cu-DOTATATE","slug":"64cu-dotatate","phase":"phase_3","mechanism":"64Cu-DOTATATE is a radioactive diagnostic imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing detection via positron emission tomography (PET).","indications":["Imaging of somatostatin receptor-positive neuroendocrine tumors","Detection and staging of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNRnN1YjB0UXRjbWJ6QjFFbFNKR2VzX2R3SUxUb2dpeWxLTjBlei1HRGZOQzExQUhmelZqMjZabG5rNkVlSFJpOHlWSGIyNXFzUFFtbTJmdFpmU1A1a05xM0I0NUtxOWtxc1ZVNU5ZZUhfVmFZeXBNNTI3U0w2SlJTOExldDFfaVl6OUZpS3E1bzJpbVRYRXRNNDJXZTB3S1E?oc=5","date":"2026-03-27","type":"pipeline","source":"BioWorld News","summary":"Radiomedix bets on alpha emitters for radiopharma’s future - BioWorld News","headline":"Radiomedix bets on alpha emitters for radiopharma’s future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMUtfWWY1bmhZYjNSTTZpcmVQMkZWNVkwcGZuS003ODRWYmEyY1ByZ3RGLVhsWnlBUTVqa3pWa3d2UHVyZWpCejg1Z2g4UmdWWjNxeXM1ZGV3M1ZmLVdBUlktWnliWEVZb2pqbFdiOFcxRlJGOWR4eVNlU0t1aFhscUtMMWlySjZGU3ZlTlpNQURvaFdJenFiRU9qMUNHRXpuZ2g0cDVPX2w?oc=5","date":"2026-01-15","type":"pipeline","source":"The Pharmaceutical Journal","summary":"Taking advantage of the radiopharmaceutical revolution - The Pharmaceutical Journal","headline":"Taking advantage of the radiopharmaceutical revolution","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPVWFYX3lkX2d4SGJsbkYtRWlXRkJMOWtkbjdTOE9RRmNaRTZvVWZOY3NIMVFkTmNIYTVBQjJueU5BZjloYTZGakxEU29hNmpNaEVadjFCbEZpc3ViMEw4OElhemFkUHREV1NXOHJzOUhxWEtDV2dhVUVvbi1LLV9GT29uT3BacnF3VkFJNmU4QUlXVENlaktkbTY5aw?oc=5","date":"2025-12-15","type":"pipeline","source":"European Biotechnology Magazine","summary":"RadioMedix expands thorium-228 supply for 212Pb - European Biotechnology Magazine","headline":"RadioMedix expands thorium-228 supply for 212Pb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOd25QRG5vLTJSRE5XcElkdnFnMG50dF96ZmNJeUFsRGVkUENtS3VxNDFqV1lBa2NLSDNuRWJBM2NfTjVQZWhNUEtWQ0FBRWhYTzlWalNST0xtYTFzQldNbGZ4YkdHWlZabHNhYmtNQ1liUjQwRldCMk44ZTVCbFk2NjIzaEt2SXVITFpENGExUnVTY0NLcVQxRHRGWXpJUVpid2V6YkU2Y1lDajF1WFBsTHRHU3hWQnVZdThRb0d2NVE5TDlHU2Nmb1pLeXY2NFRlb19wQUxRY1VDNEVTa3lpWWREdDM3U21oYlJHaGo1X0pySTZPeHNuVmRXLUI?oc=5","date":"2025-12-12","type":"pipeline","source":"GlobeNewswire","summary":"RadioMedix Expands Thorium-228 Supply Network Through New Agreement With Van Overeem Nuclear B.V. - GlobeNewswire","headline":"RadioMedix Expands Thorium-228 Supply Network Through New Agreement With Van Overeem Nuclear B.V.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxORDIzQ0VtQlEwUEdXbWp4TzNsaEp2LUgwal83VUpjQlRpRzlzTjhTRFlCN1UzbkduUkVCZmY2MHBpbS1rV0V6WFBLLWFRMUVNVVNTODJ1U1I3emlnNExnX2xaMHZKY0lxeEV6MTFVM2xlaXgxMnVhVFNYN3gzaGNSa0o2bFQwWUo3TFV0QlRRbXZJOTFkWmc?oc=5","date":"2025-10-09","type":"deal","source":"Life Science Leader","summary":"Partnering To Commercialize Radiopharmaceuticals - Life Science Leader","headline":"Partnering To Commercialize Radiopharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE4zcEpFeHozdWQ3TTFaYXQ1cHFZVnVKTnlveDNFZ29IcEZHRjBVRmpKZTJpbHhLeDRhck9aOWhJemFOR1RYcEc2UVEwQjRnLXptREEyNXc4OU9kWTFfTTNQaEV4NUVmVDMydGc?oc=5","date":"2025-09-03","type":"pipeline","source":"Labiotech.eu","summary":"Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand - Labiotech.eu","headline":"Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNZGttUFZhYW04Y2pWaXRzdEhQQXFsY3k5TlY5d2pGT1EyNkE4UEx6YWE5SVhxeTdYVnFVZEt3QXYwbmh0MDdPWGJ5d19VZlFOWDh1N2pBcmtvNlRLVk9EYjRnVVQ2aUtQT2RpWHlVQVlzVjM3Vk1YaDNlWDI2Z2IxZzBUcUpyR1JNQXVwWk0xQ3hxZGE2N3dpRkVqVGJuRFR4RlE?oc=5","date":"2025-06-12","type":"regulatory","source":"Bioprocess Online","summary":"Peeling Back The Layers Of Radiolabeled Peptide Production - Bioprocess Online","headline":"Peeling Back The Layers Of Radiolabeled Peptide Production","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcVh6NDlXc1ZyT0xpalFyZjFEaDdlX3JaTzFFRkNEWjhZbG14MExLcXlKWFN1WmJuSDNuUWlRT1RSYkI4U0pNaDRkYlhiWHJoWVRYU1NGckd5eDlCdzh5Z05VV3FYN0lSdVAtNUxlWUJrTExBWkltdXV1N0U2S1dWWlZ2Q3p0RmJzM2hoaU9jeEZDQmdudGMxV25zekIyMGUxeWZIM01jMGlGTXZhY3R1WEo1eEZWQ3hUakU0?oc=5","date":"2025-06-06","type":"pipeline","source":"Drug Target Review","summary":"Why radiopharmaceuticals are gaining ground in the fight against cancer - Drug Target Review","headline":"Why radiopharmaceuticals are gaining ground in the fight against cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOS2ttWFJ5aEJ3WGIxaTAySGFsYnNud040akZSRzB3MG5kam9Ma2dGXzY2WmdrTXEtclgxdi1ZdUZDbmRWcHBmVmxWZGh3NmtPX2l3dVdMQ2ZNVVlIYUlnVmYzaTZqMDdvZ0dDWHQ2QmRjVVBCMEk0dWRFb3M2TXhKUldweWFOaDBfSDVwMlpnVGluRW4tdENTQ2ltdkM?oc=5","date":"2025-03-13","type":"pipeline","source":"BioSpace","summary":"Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace","headline":"Houston’s Life Sciences Scene Continues Boosting Its Reputation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOd2J3bnEzSkpVZWZTWkNSLVo1cUlCNnZVNk1la0tSd3FocjV4ZkJRbnU5UDhpc2plYkstNS1IdkdrMjVaTVZJaXI4dm4yNUFHbGUtMWhPaGVScDhQcTZqMDhoNFA4eXMzYUs4OWlmSmotQXdreUV1NVdVQlNqaElHRmMzZ2lOSUdPNENqczlRTHNoTXU5UWllYkk1T0loYlJVRVZZNm10N29mdHRzazJxNTd6ZWM?oc=5","date":"2024-09-12","type":"pipeline","source":"MedCity News","summary":"Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug - MedCity News","headline":"Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxQVXBvdktXTXJYTklWNk9Ua0ZCd3BvWmdWTmNMaGZqcUIyUERuSHQwWFFzTDBTU0gtVGw1bkVhT0VQc0xIR1FYOS1GUXpoUzRYaXlMdDdBWXo2MHJwb0RIOGIxOWJ4SVBlN3hDU0ZqLWN1VVZxdWlCWXFwUkdUaTFrNW9VTUctcjU5NXpLcFNoblEyazUxZkJOMTZnbjM4WVBxRUtBVnV2aWRJbjBuekNQUHVqUkExcFdhYmFvUGFWT1o3MUxrbzJyNUJQMnV5LWhvQ3M4aVgtRlAtZjVGdmlTanJUeVpoVUkyYzZpNkFBS0h5c3RCS3JhUFIxVHhtZUxIblhNbTZVUUZEMmRDOWN2WnYzb3hTY1hBUlNB?oc=5","date":"2024-02-12","type":"regulatory","source":"Business Wire","summary":"RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedix - Business Wire","headline":"RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedix","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxORHRJQ3lkcnlWVFd1TU4xNTVNaWphRzFjemJsendaZjNRQ0V4cXR0d2gyWkRubXhVcEhFZjZPakU3Yy1YbXNnVHo1bndKVHBDdkN2b3QzcWlReWR1MF9BcnljSkplUDVuLUdGMXVDd2pjbk9yaFozWGlxZ3oydEtHMUMzaURZdTcxSURub2lYTk1oblVVblJoN3BQOWE1NG01V185Z2kwdHI2dHhnbUE4NGxRQkEtakotRVhsTGthY05ScVB1dmtYSnlYd3NOYkdEUGVBZGdKWElhSTBFYVV5VG1vUkVMUHBFcElUOEx5ZE5DbnNZUXo2SlZ5ZW1jcmhQYUxVZUJIMG5aaVNWeXhHanpPcXJDNVhSQW9FampaeWFYdDlHN0s4Z2RR?oc=5","date":"2023-02-13","type":"trial","source":"PR Newswire","summary":"Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer - PR Newswire","headline":"Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrat","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}